New multiplex real-time PCR test simultaneously detects 29 respiratory viruses, including Influenza A subtypes in less than 5 hours
ROCKVILLE, Maryland and SEOUL, Korea, November 1, 2010 – Just in time for the flu season Seegene today announced the availability of a new respiratory multiplex molecular diagnostic test that accurately identifies 29 respiratory viruses, including Influenza A subtypes. The new MagicplexTM RV Panel Real-time test will enable doctors and clinicians to diagnose in less than five hours what type of pathogen is infecting a patient’s respiratory system. Seegene’s MagicplexTM RV Panel Real-time test will be on display in Seegene’s booth at MEDICA 2010, held in Düsseldorf, Germany, November 17-20.
In recent years populations around the world are warned that this year’s influenza strain might trigger a pandemic. According to World Health Organization (WHO), mortality rate of ages younger than five caused by severe respiratory disease is 20%, of which 90% is caused by pneumonia.
But with so many types of respiratory pathogens and symptoms, it is difficult to make an accurate and potentially life saving diagnosis – a bacterium needing an antibiotic; a virus needing an antiviral; or something requiring bed rest.
Seegene’s MagicplexTM RV Panel Real-time Test will help clinicians get quick and accurate answers. The 29 pathogens that the test detects are: influenza A virus (Flu A), influenza B virus (Flu B), human respiratory syncytial virus A/B (RSV A/B), human adenovirus A/B/C/D/E/F (AdV A/B/C/D/E/F), human coronavirus 229E/NL63/OC43 (CoV 229E/NL63/OC43), human enterovirus (HEV), human rhinovirus A/B/C (HRV A/B/C), human bocavirus 1/2/3/4 (HBoV1/2/3/4), and human parainfluenza virus 1/2/3/4 (PIV1/2/3/4).
Additionally, Flu A can be further analyzed into 2009 Pandemic H1, human H3, and human H1 by using Flu A Real-time Subtyping set.
“By specifically identifying the type of virus or bacterial infection a patient has enables physicians to treat patients with a form of personalized medicine by knowing the correct drug therapy to treat the patient,” said Jong-Yoon Chun, chief executive officer of Seegene. “Current tests for respiratory viruses and bacteria, such as viral culture, rapid culture or rapid Ag test, are not up to the challenge of cost-effective, personalized healthcare. By varying by degrees those tests are laborious, time consuming, low sensitivity, and limited in the scope of pathogen types tested for, and specimen used.”
MagicplexTM RV Panel Real-time Test is based on Seegene’s proprietary READ™ (Real Amplicon Detection) technology, which combines the advantages of a multiplex format with a real-time PCR system. MagicplexTM tests work in a simple two-step process: first amplify the DNA/RNA sequence of the target pathogens, then simply read those signals using any real-time PCR instrument. The result is a molecular diagnostic testing approach that sets a new standard for efficiency, specificity, and sensitivity.
MagicplexTM tests are not available in the USA until approved by the FDA.
Seegene, Inc. is a leading molecular diagnostics company developing, manufacturing and marketing innovative “multiplex” (or “multi-pathogen detection”) molecular diagnostic products and services. It holds proprietary technologies of both PCR and Real-time PCR named ACP™, DPO™, and READ™, which sets a standard in high-throughput and simultaneous multi-pathogen detection called “multiplex PCR.” The novel multiplex Real-time PCR technology, READ™, overcomes the limitations of conventional Real-time PCR, providing dramatic improvement in sensitivity and specificity. Seegene holds three novel Molecular diagnostic platforms: Seeplex® system adapting DPO™ Technology, AnyplexTM and MagicplexTM system which are Real-time PCR detection platform adapting DPO™ and READ™ Technology. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.
For more information please visit www.seegene.com or call +301-762-9066.